Point72 Asia (Singapore) Pte. Ltd. Adagio Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 28,364 shares of ADGI stock, worth $93,884. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,364
Previous 56,603
49.89%
Holding current value
$93,884
Previous $40.5 Million
22.91%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding ADGI
# of Institutions
82Shares Held
153MCall Options Held
244KPut Options Held
167K-
Janus Henderson Group PLC London, X025.4MShares$84 Million0.04% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct20.3MShares$67.2 Million0.13% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx19MShares$62.8 Million0.93% of portfolio
-
Ra Capital Management, L.P. Boston, MA17.1MShares$56.7 Million0.97% of portfolio
-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million19.18% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...